Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease
Primary Purpose
Crohn Disease, Pregnancy
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Diet-CD
Sponsored by
About this trial
This is an interventional supportive care trial for Crohn Disease focused on measuring Microbiota, Diet, Immune System
Eligibility Criteria
Inclusion Criteria:
- Capacity to sign informed consent
- At least 18 years old
- Singleton pregnancy of less than 27-29 weeks gestation
- English-speaking
Exclusion Criteria:
- Inability to provide informed consent
- HIV/AIDS
- Multi-fetus pregnancy
- Fetal chromosomal or structural abnormalities
- Active infection (including chorioamnionitis or sepsis)
- Alcohol use disorder
- Diagnosis of diabetes, renal disease, or intrauterine growth restriction
- Non-English speaking
- Active perianal or extraintestinal disease
- Antibiotic or steroid treatment at recruitment
- Scheduled cesarean section prior to gestational week 37
Sites / Locations
- University of Massachusetts Medical School
- Icahn School of Medicine at Mount Sinai
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
No Intervention
No Intervention
Arm Label
Diet-CD
No-Diet-CD
No-Diet-Control
Arm Description
dietary intervention: 8-10 weeks of diet intervention
Usual diet with no intervention
Unaffected controls at the same gestational stage will follow usual diet and no intervention
Outcomes
Primary Outcome Measures
Change in overall number of proteobacteria
Change in overall number of proteobacteria in pregnant CD patients at 4 years as compared to baseline
Secondary Outcome Measures
Calprotectin level
Calprotectin is a stool marker of inflammation
Harvey Bradshaw index (HBI)
Assessments of CD symptom severity
SF-12
Quality of life will be assessed using the SF-12.
Mental and physical functioning is assessed by the Medical Outcomes Study Short Form 12 (SF-12) Health Survey. The questions in the SF-12 target eight dimensions of health and are weighted and summed to provide two composite measures, the Physical Composite Scale and Mental Composite Scale (PCS and MCS). The PCS and MCS are scored to range from 0 to 100, with 0 indicating the lowest level of health and 100 indicating the highest level of health.
The Rome IV Criteria
The Rome IV Criteria for Functional Gastrointestinal Disorders in Infants will be used to assess infant's functional gastrointestinal disorders at 3 months of age. The Rome IV is a validated diagnostic criteria used to improve clinical care in infants and toddlers, adequately diagnose functional gastrointestinal disorders in order to provide proper treatment, and improve homogeneity in research study design.
The Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)
The CES-D is a 20-item measure assessing symptoms of depression based on a 4-point Likert scale ranging from 0 -3, with higher score indicating more depression.
and depressive disorder. The symptoms it measures are those defined by the American Psychiatric Association Diagnostic and Statistical Manual (DSM-V) for a major depressive episode.
The Bristol Stool Form Scale
A validated 7 point scale used extensively in clinical practice and research for classification of stool form. The scale is from 1-7 and a higher score indicates looser stool. A score of 1 is classified as "separate hard lumps, like nuts (hard to pass), while a score of 7 is classified as "Watery, no solid pieces (entirely liquid)."
Alternative Healthy Eating Index
Alternative Healthy Eating Index (AHEI) - total score ranging from 2.5 (least desirable) to 87.5 (most desirable) dietary pattern
Full Information
NCT ID
NCT03850600
First Posted
February 15, 2019
Last Updated
September 15, 2023
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, University of Massachusetts, Worcester
1. Study Identification
Unique Protocol Identification Number
NCT03850600
Brief Title
Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease
Official Title
The MELODY Trial: Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 30, 2019 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, University of Massachusetts, Worcester
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The MELODY Trial: Modulating Early Life Microbiome through Dietary Intervention in Crohn's Disease, will test whether a non-invasive dietary intervention during pregnancy can improve the gut microbiota composition in both pregnant Crohn's disease patients and their babies during the sensitive time window of infant immune system development, and whether this can lead to decreased risk of maternal disease relapse postpartum and decreased functional gastrointestinal disorders and gut inflammation in their babies. Through this trial, the study team hopes to better understand the origin of the initial gut bacterial colonization in babies, providing potential intervention targets to prevent Crohn's disease development in high risk individuals.
Detailed Description
The study design is a three-arm, prospective, pre-post intervention trial. Crohn's Disease (CD) patients at 27-29 weeks of pregnancy will self-select to Arm 1 or Arm 2. Controls will be in Arm 3.
Arm 1 (diet-CD): 8-10 weeks of dietary intervention (n=66)
Arm 2 (no-diet-CD): usual diet with no diet intervention (n=66)
Arm 3 (no-diet-control): unaffected controls at the same gestational stage will follow their usual diet and no intervention (n=66).
The goal of this study is to prospectively test the hypothesis that a non-invasive dietary intervention during the last trimester of pregnancy could beneficially shift the microbiome of CD patients and their babies, hereby promoting a healthier immune system during a critical time of the immune system development. Particularly, the study team will test whether favorable diet-driven changes in the microbiome can lead to a reduced risk of postpartum relapse and lower gut inflammation in the offspring.
Stool, saliva, breast milk and umbilical cord blood samples will be collected, and questionnaires administered. Self-selected participants to Arm 1 will adopt a specified diet, which will be adapted to address specific needs of third trimester pregnancy without compromising the diet principles. Subjects will receive nutritional counseling and training, and compliance to dietary recommendations will be recorded.
Analysis will be performed to correlate dietary change and assessed changes in quality of life with microbial composition in the gut and with circulating markers of inflammation in moms. The study team will also compare the effect of diet vs. non-diet on babies' microbiome and the impact of the early life microbiome in levels of inflammatory markers after 1-year of partum.
This study will help better understand the origin of the initial bacterial colonization in high-risk babies, providing potential intervention targets for primary CD prevention. The study team will also generate an extensive collection of serial samples and longitudinal clinical data, including identification of specific dietary components correlated with certain functional and quantitative bacterial patterns for future investigations. This study will help create new opportunities to foster a healthy microbiome in high risk babies of microbiome and immunity-mediated diseases, thereby hopefully reducing their risk later in life.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn Disease, Pregnancy
Keywords
Microbiota, Diet, Immune System
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The study design is a three-arm, prospective, pre-post intervention trial. Crohn's Disease (CD) patients at 27-29 weeks of pregnancy will self-select to Arm 1 or Arm 2. Controls will be in Arm 3.
Arm 1 (diet-CD): 8-10 weeks of dietary intervention (n=66)
Arm 2 (no-diet-CD): usual diet with no intervention (n=66)
Arm 3 (no-diet-control): unaffected controls at the same gestational stage will follow their usual diet and no intervention (n=66).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
194 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diet-CD
Arm Type
Experimental
Arm Description
dietary intervention: 8-10 weeks of diet intervention
Arm Title
No-Diet-CD
Arm Type
No Intervention
Arm Description
Usual diet with no intervention
Arm Title
No-Diet-Control
Arm Type
No Intervention
Arm Description
Unaffected controls at the same gestational stage will follow usual diet and no intervention
Intervention Type
Other
Intervention Name(s)
Diet-CD
Other Intervention Name(s)
Diet Arm
Intervention Description
CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
Primary Outcome Measure Information:
Title
Change in overall number of proteobacteria
Description
Change in overall number of proteobacteria in pregnant CD patients at 4 years as compared to baseline
Time Frame
Baseline and 4 Years
Secondary Outcome Measure Information:
Title
Calprotectin level
Description
Calprotectin is a stool marker of inflammation
Time Frame
4 Years
Title
Harvey Bradshaw index (HBI)
Description
Assessments of CD symptom severity
Time Frame
4 Years
Title
SF-12
Description
Quality of life will be assessed using the SF-12.
Mental and physical functioning is assessed by the Medical Outcomes Study Short Form 12 (SF-12) Health Survey. The questions in the SF-12 target eight dimensions of health and are weighted and summed to provide two composite measures, the Physical Composite Scale and Mental Composite Scale (PCS and MCS). The PCS and MCS are scored to range from 0 to 100, with 0 indicating the lowest level of health and 100 indicating the highest level of health.
Time Frame
4 Years
Title
The Rome IV Criteria
Description
The Rome IV Criteria for Functional Gastrointestinal Disorders in Infants will be used to assess infant's functional gastrointestinal disorders at 3 months of age. The Rome IV is a validated diagnostic criteria used to improve clinical care in infants and toddlers, adequately diagnose functional gastrointestinal disorders in order to provide proper treatment, and improve homogeneity in research study design.
Time Frame
3 months
Title
The Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)
Description
The CES-D is a 20-item measure assessing symptoms of depression based on a 4-point Likert scale ranging from 0 -3, with higher score indicating more depression.
and depressive disorder. The symptoms it measures are those defined by the American Psychiatric Association Diagnostic and Statistical Manual (DSM-V) for a major depressive episode.
Time Frame
4 Years
Title
The Bristol Stool Form Scale
Description
A validated 7 point scale used extensively in clinical practice and research for classification of stool form. The scale is from 1-7 and a higher score indicates looser stool. A score of 1 is classified as "separate hard lumps, like nuts (hard to pass), while a score of 7 is classified as "Watery, no solid pieces (entirely liquid)."
Time Frame
4 Years
Title
Alternative Healthy Eating Index
Description
Alternative Healthy Eating Index (AHEI) - total score ranging from 2.5 (least desirable) to 87.5 (most desirable) dietary pattern
Time Frame
4 Years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Capacity to sign informed consent
At least 18 years old
Singleton pregnancy of less than 27-29 weeks gestation
English-speaking
Exclusion Criteria:
Inability to provide informed consent
HIV/AIDS
Multi-fetus pregnancy
Fetal chromosomal or structural abnormalities
Active infection (including chorioamnionitis or sepsis)
Alcohol use disorder
Diagnosis of diabetes, renal disease, or intrauterine growth restriction
Non-English speaking
Active perianal or extraintestinal disease
Antibiotic or steroid treatment at recruitment
Scheduled cesarean section prior to gestational week 37
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Inga Peter, PhD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Barbara Olendzki, RD,MPH, LDN
Organizational Affiliation
University of Massachusetts, Worcester
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ana Maldonado-Contreras, PhD
Organizational Affiliation
University of Massachusetts, Worcester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Massachusetts Medical School
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease
We'll reach out to this number within 24 hrs